ArticleMolecular and clinical oncology2017

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).

Masayoshi Miyawaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.